Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 19Recruiting 14Active not recruiting 8Terminated 5Unknown 2Withdrawn 1Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, Mantle-Cell 3Lymphoma, B-Cell 3Lymphoma, Large B-Cell, Diffuse 2Lymphoma 2Leukemia, Lymphocytic, Chronic, B-Cell 2Lymphoma, Non-Hodgkin 1Lymphoma, Follicular 1Leukemia, B-Cell 1Dendritic Cell Sarcoma, Interdigitating 1

Interventions

Lenalidomide 4Rituximab 3zanubrutinib 2tafasitamab 2fludarabine 2Magnetic Resonance Spectroscopy 2Cyclophosphamide 2vorasidenib 1tislelizumab 1resiniferatoxin 1relmacabtagene autoleucel 1pomalidomide 1orelabrutinib 1obinutuzumab 1loncastuximab tesirine 1duvelisib 1Transurethral Resection of Bladder 1Temozolomide 1Standard of Care 1Spinal Puncture 1Specimen Handling 1Radiotherapy, Intensity-Modulated 1Prednisone 1Oxygen Consumption 1Interleukin-2 1Inhalation 1Furosemide 1Eflornithine 1Diet 1Bendamustine Hydrochloride 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Lymphoma, Follicular × obinutuzumab × Clear all
NCT06549335 2024-10-15

Zanubrutinib, Obinutuzumab and Lenalidomide (ZGR) in High-risk Treatment-naive Patients with Follicular Lymphoma (FL)

Ruijin Hospital

Phase 2 Not yet recruiting
66 enrolled
Lymphoid

Lymphoma, Lymphoma, Follicular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡